Common Contracts

REGISTRATION RIGHTS AGREEMENT

Registration Rights Agreement • August 31st, 2022 • Quotient LTD • In vitro & in vivo diagnostic substances • New York

• Contract Type
  Registration Rights Agreement
• Filed
  August 31st, 2022
• Company
  Quotient LTD
• Industry
  In vitro & in vivo diagnostic substances
• Jurisdiction
  New York

This Agreement is being entered into in connection with the execution and delivery of the Sixth Supplemental Indenture, dated as of July 6, 2022, by and among the Company, the guarantors party thereto, and the Holders (the “Sixth Supplemental Indenture”) which supplements and amends the Indenture, dated as of October 14, 2016 by and among Company, the guarantors party thereto, and the Holders (as subsequently amended, the “Indenture”). The Holders collectively own all of the Company’s 12.00% Senior Secured Notes issued pursuant to the terms of the Indenture (the “Notes”). In consideration of the Holders’ execution and delivery of the consents that are required for the effectiveness of the Sixth Supplemental Indenture, the Company has issued warrants (“Warrants”) that entitle the holders to purchase an aggregate of 8,494,595 of the Company’s Ordinary Shares (such Ordinary Shares, together with any Ordinary Shares issuable upon exercise of any Penalty Warrants, the “Warrant Shares”).

REGISTRATION RIGHTS AGREEMENT

Registration Rights Agreement • October 14th, 2021 • Quotient LTD • In vitro & in vivo diagnostic substances

• Contract Type
  Registration Rights Agreement
• Filed
  October 14th, 2021
• Company
  Quotient LTD
• Industry
  In vitro & in vivo diagnostic substances

This Agreement is being entered into in connection with the execution and delivery of the Fourth Supplemental Indenture, dated as of October 13, 2021, by and among the Company, the guarantors party thereto, and the Holders (the “Fourth Supplemental Indenture”) which supplements and amends the Indenture, dated as of October 14, 2016 by and among Company, the guarantors party thereto, and the Holders (as subsequently amended, the “Indenture”). The Holders collectively own all of the Company’s 12.00% Senior Secured Notes issued pursuant to the terms of the Indenture (the “Notes”). In consideration of the Holders’ execution and delivery of the consents that are required for the effectiveness of the Fourth Supplemental Indenture, the Company has issued to the Holders (1) an aggregate of 932,772 of the Company’s ordinary shares, nil par value per share (the “Consent Shares”) and (2) warrants (the “Warrants”) to purchase an aggregate of 1,844,020 of the Company’s ordinary shares, nil par valu